tetano
Editor, Senior Moderator
Acta Biomed
. 2021 Sep 2;92(4):e2021271.
doi: 10.23750/abm.v92i4.11787.
Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature
Kamleshun Ramphul[SUP] 1 [/SUP], Renuka Verma[SUP] 2 [/SUP], Nomesh Kumar[SUP] 3 [/SUP], Yogeshwaree Ramphul[SUP] 4 [/SUP], Stephanie Mejias[SUP] 5 [/SUP], Petras Lohana[SUP] 6 [/SUP]
Affiliations
Abstract
As the world continues to struggle with the pandemic of COVID-19 (coronavirus disease 2019), several cases of mucormycosis have been reported in these patients with a high mortality rate. We conducted a review of literature and found 19 articles with 20 patients who developed mucormycosis during their COVID-19 infection.14 (70%) were males, and 6(30%) were females. While their mean age was 52.2 ± 17.3, affected men were older than females. Ten (50%) patients also had diabetes. Common clinical findings included ophthalmologic complaints, fever, shortness of breath, and facial pain. Amphotericin B was the most common antifungal used and 40% of cases needed surgical management of the infection. Steroid use was reported in around 12 cases (60%). Unfortunately, the mortality rate was 65% in this group of patients. Several changes in care should be brought for a consistent prevention, early diagnosis, and strong management of mucormycosis in COVID-19 patients.
. 2021 Sep 2;92(4):e2021271.
doi: 10.23750/abm.v92i4.11787.
Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature
Kamleshun Ramphul[SUP] 1 [/SUP], Renuka Verma[SUP] 2 [/SUP], Nomesh Kumar[SUP] 3 [/SUP], Yogeshwaree Ramphul[SUP] 4 [/SUP], Stephanie Mejias[SUP] 5 [/SUP], Petras Lohana[SUP] 6 [/SUP]
Affiliations
- PMID: 34487063
- DOI: 10.23750/abm.v92i4.11787
Abstract
As the world continues to struggle with the pandemic of COVID-19 (coronavirus disease 2019), several cases of mucormycosis have been reported in these patients with a high mortality rate. We conducted a review of literature and found 19 articles with 20 patients who developed mucormycosis during their COVID-19 infection.14 (70%) were males, and 6(30%) were females. While their mean age was 52.2 ± 17.3, affected men were older than females. Ten (50%) patients also had diabetes. Common clinical findings included ophthalmologic complaints, fever, shortness of breath, and facial pain. Amphotericin B was the most common antifungal used and 40% of cases needed surgical management of the infection. Steroid use was reported in around 12 cases (60%). Unfortunately, the mortality rate was 65% in this group of patients. Several changes in care should be brought for a consistent prevention, early diagnosis, and strong management of mucormycosis in COVID-19 patients.